DOBESILIC ACID

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C6H6O5S
Molecular Weight	190.174
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

OC1=CC=C(O)C(=C1)S(O)(=O)=O

InChI

InChIKey=IKQCSJBQLWJEPU-UHFFFAOYSA-N

InChI=1S/C6H6O5S/c7-4-1-2-5(8)6(3-4)12(9,10)11/h1-3,7-8H,(H,9,10,11)

HIDE SMILES / InChI

Molecular Formula	C6H6O5S
Molecular Weight	190.174
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Calcium dobesilate (brand name Doxium) is a veno-tonic drug, which is widely prescribed in more than 60 countries from Europe, Latin America, Asia and the Middle East for three main indications: chronic venous disease, diabetic retinopathy and the symptoms of haemorrhoidal attack. This drugs also in the phase III of clinical trial is an effective adjuvant therapy, with an absence of significant side-effects, in patients with venous ulcers and stasis dermatitis. It was suggested, that the inhibitory effect of calcium dobesilate on platelet function is mediated through the cyclic AMP pathway, and probably through activation of adenyl cyclase.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
prostaglandin biosynthetic process 23	Inhibitor 8,297
platelet activation 9	Activator 1,430
cAMP signaling pathway 8	Activator 1,430
Adenylate cyclase 13	Activator 1,430

Conditions

Condition	Modality	Highest Phase	Product
Chronic venous insufficiency 12	Primary	Approved 8,429	Doxium
Diabetic microangiopathy 6	Primary	Approved 8,429	Doxium
Venous ulcers 6	Primary	Phase III 656	Doxium
Hemorrhage 11	Primary	Approved 8,429	DICYNONE

PubMed

Show entries

Title	Date	PubMed
Clinical and experimental studies on the action of ethamsylate on haemostasis and on platelet functions.	1980 Sep 15	7193361
Etamsylate as inhibitor of prostaglandin biosynthesis in pregnant human myometrium in vitro.	1981 Nov 15	7319004
Effects of etamsylate on platelet functions and arachidonic acid metabolism.	1982 Dec 27	6819650
The hemostatic agent ethamsylate enhances P-selectin membrane expression in human platelets and cultured endothelial cells.	2002 Sep 15	12565720
The hemostatic agent ethamsylate promotes platelet/leukocyte aggregate formation in a model of vascular injury.	2004 Aug	15312148

Showing 1 to 5 of 9 entries

Previous1 2Next

Patents

Sample Use Guides

In Vivo Use Guide

Oral. Menorrhagia - The recommended dose is 500 mg 4 times/day during menstruation. Control of hemorrhage after surgery - The recommended dose is 250-500 mg 4-6 hourly as needed. Adults. Presurgical: 1-2 ampoules i.v. or i.m. (250-500mg) 1 hour before surgery. Persurgical: 1-2 ampoules i.v. Repeat the dosage if necessary. Postsurgical: 1-2 ampoules (250-500mg) every 4-6 hours as long as the risk of bleeding persists. Emergency cases, according to the severity of the case: 1-2 ampoules i.v. or i.m. every 4-6 hours as long as the bleeding risk persists. Local treatment: soak a swab with the contents of one ampoule and apply to haemorrhagic area, or in the tooth socket after dental extraction. The application may be repeated if necessary; it may be associated with oral or parenteral administration. Children. Half the adult dose. Neonatology: 10mg per kg body weight (0,1ml=12,5mg) injected intramuscularly within 2 hours of birth then every 6 hours for 4 days.

Route of Administration: Other

In Vitro Use Guide

Under basal conditions, ethamsylate was unable to modify whole-blood platelet-leukocyte aggregation, but following whole-blood perfusion through a damaged vessel, ethamsylate produced a modest, but significant increase in platelet-leukocyte aggregates at concentrations 20-40 uM